Tracey Lamb, PhD

Assistant Professor

Pediatrics, Infectious Diseases

ARTDTP Research Discipline

The Lamb lab is currently developing two different approaches for the treatment of infectious diseases, concentrating on malaria as the target disease. The first exploits Eph receptors, the largest family of tyrosine kinase receptors, which we have shown contribute to the pathogenesis of malaria infection. Eph receptors appear to augment trafficking of activated T cells to areas of sequestered parasitized red blood cells. Therefore, Eph-based adjunct therapies for blocking Eph receptors in malaria infection have potential to reduce T cell-mediated pathology in conjunction with anti-parasite therapies, particularly in patients infected with drug-resistant malaria parasites. In addition to malaria, the Eph receptors represent therapeutic targets for other infections where T- cell mediated pathology is prominent. A second venue of research in the Lamb lab is focused on the development of a mucosally-targeted oral vaccine delivery system using genetically modified probiotic yeast to deliver vaccinogens complexed with adjuvant. This vaccine delivery system will be easy to grow, store and administer making it an ideal delivery system for diseases of the developing world. They are currently testing the vaccine delivery system in mice using the model antigen chicken ovalbumin and a number of intestinal pathogens. The group plans to investigate the capacity of this system to generate systemic protective immune responses to malaria antigens using mouse models of malaria infection. Lastly Dr Lamb is the Deputy Director of the Immuneprofiling Core on a large multi-PI contract headed by Professor Mary Galinski. The work in this contract will use systems biology to model the host-pathogen interaction in clinical malaria and determine biomarkers of diseases with non-human primate malaria model systems. 

ARTDTP Faculty Collaborators

Mary R. Galinski, PhD

Jan R. Mead, PhD